We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 17, 2006
Last Update Posted: February 17, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Indonesia University
Information provided by:
Showa University
October 16, 2006
October 17, 2006
February 17, 2010
October 2006
November 2009   (Final data collection date for primary outcome measure)
preeclampsia cases
Same as current
Complete list of historical versions of study NCT00388856 on ClinicalTrials.gov Archive Site
adverse pregnancy outcome
Same as current
Not Provided
Not Provided
Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status
Vitamin C and E Supplementation in Pregnant Women With Low Antioxidant Status
The purpose of this study is to investigate antioxidants supplementation in pregnant women with low antioxidant status at 10-12 weeks gestation age in relation to adverse pregnancy outcome in randomized prospective study.

Preeclampsia still remains a leading cause of feto-maternal mortality and morbidity in developed and developing world. Despite of intensive research, the underlying pathologic mechanisms of this disease remain elusive. It has been agreed that incomplete or absent transformation of spiral arteries by replacing endothelial cells and mural vascular smooth muscle cells has been observed in the placental bed of preeclamptic patients and severe cases of intrauterine growth restriction. Oxidative stress has been proposed as a link between these mechanisms. However, it has been demonstrated by two large studies that antioxidant supplementation does not reduce the risk of preeclampsia. Our initial study has been shown that antioxidant supplementation may be reduce the risk of preeclampsia in pregnant women with low antioxidant status.

Comparison(s): adverse pregnancy outcome between vitamin C and E given and placebo given to pregnant women with low antioxidant status at 10-12 weeks gestation age

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Drug: Vitamin C 1000mg and E 400IU
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2010
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Agree to consent form, and consent to protocol of research
  • Known healthy singleton 6-10 weeks pregnant women

Exclusion Criteria:

  • Blood pressure > 135/85
  • Proteinuria
  • History or current use of anti-hypertensive medication or diuretics
  • Use of vitamins C > 150 mg and/or E > 75 IU per day
  • Pregestational diabetes
  • Known placental abnormalities.
  • Current pregnancy is a result of in vitro fertilization
  • Regular use of platelet active drugs or non-steroidal anti-inflammatory drugs
  • Known fetal abnormalities
  • Documented uterine bleeding within a week of screening
  • Uterine malformations
  • History of medical complications
  • Illicit drug or alcohol abuse during current pregnancy
  • Intent to deliver elsewhere
  • Known psychologic problems.
  • Participating in another interventional study
Sexes Eligible for Study: Female
17 Years to 45 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Yuditiya Purwosunu, Univ. Indonesia
Showa University
Indonesia University
Principal Investigator: Akihiko Sekizawa, MD, PhD Showa University School of Medicine
Showa University
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP